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1. Introduction  
Many cancer patients have medicated themselves with traditional herbal remedies, which 
are mostly composed of a single or combined medicinal plants. The effectiveness of the 
remedies can be explained by the presence of the phytochemicals and the bioactivity. The 
investigators select the traditional-used and evidence-based herbs for the research and 
development. The investigation of the following Thai herbs and their reasonable utilization 
are presented.  
2. The selected medicinal plants 
2.1 Single plant 
2.1.1 Trichosanthes cucumerina L. 
It is a cucurbitaceous vine, grooved stem with scattered hairs and tendrils. The leaf is 
simple, alternate, five-lobed margin and 8-12 cm blade width. It is dioecious, the male 
flower is white and the female yellow. The fruit is round with pointed ends and green 
striped lengthwise, usually 3-4 cm wide and 5-6 cm long (Fig. 1). 
It is distributed wildly in the tropical Asia, climbs over the big trees along the riverside and 
mixed forest. The fruit is very bitter and inedible. It is used for shampooing to relieve itching, 
dandruff and lice. The fruit and the aerial plant parts are the ingredients in traditional Thai 
herbal medicine for dizziness. The dried fruit is ground, mixed with tobacco and smoked to 
alleviate the asthma. The seed (20-30 seeds) is an emetic, antidysentery, febrifuge, emenagogue 
and anthelmintic. The root decoction is laxative, febrifuge and used to relieve headach and 
bronchitis. The vine is decocted and used as febrifuge, laxative and tonic. 
The bitterness of T. cucumerina fruit arises from the presence of cucurbitacins, the highly 
oxygenated C30-triterpenes, which are frequently found in the cucurbitaceous plants. The 
fruit juice was extracted with diethyl ether. The extract was concentrated and the crystalline 
solid was produced. The marc was continuously extracted with petroleum ether, chloroform 
and methanol in a Soxhlet apparatus. We tested the biological activities of the fruit juice, 
crystalline solid (TC compound) and the methanol extract. The fruit juice which was 
prepared as lyophilized (spray dried) solid, did not inhibit the standard strains of the 
microorganism (E. coli, S. aureus, B. subtitis, M. smegmatis and C. albicans), whereas the  
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Fig. 1. Trichosanthes cucumerina L. : A whole plant; B fruit; C flower; D root. 
methanol extract inhibited S. aureus, M. smegmatis and had a bactericidal action against C. 
diptheriae (Tiangda et al, 1986). TC compound comprised cucurbitacin B (Fig. 2) and 
dihydrocucurbitacin B, which had a strongly cytotoxic action, in vitro, against KB cell 
(human nasopharynx carcinoma cell) (Silapaarcha et al, 1981; Jiratchariyakul et al, 1992).  
The MTT colorimetric assay for cytotoxicity against breast cancer cell line (SKBR3) of the TC 
compound, cucurbitacin B and dihydrocucurbitacin B resulted the ED50 of 0.48, 0.05 and 0.40 
g/mL, respectively (Jiratchariyakul et al, 1999). The lyophilized fruit juice of 5 mg/kg body 
weight was injected peritoneally to Swiss albino mice exhibited no sign of toxicity as in the 
control group. The LD50 of the juice was 13 mg/kg body weight, which was considered as 
moderate toxicity according to Casarett and Doull (Tiangda et al, 1986; Casarett  Doull, 1975). 
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Fig. 2. Structure of cucurbitacin B. 
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The antiproriferative effect of the fruit juice and the isolated cucurbitacin against four breast 
cancer cell lines was further carried out. The cell lines included SKBR3, MCF7, T47D and 
MDA-MB435. SKBR3 is a human breast cancer cell line with overexpression of the HER2/neu 
receptor and absence of the ER receptor. In contrast, T47D and MCF7 are breast cancer cell 
lines that are ER receptor positive and HER2/neu negative, whereas the MDA-MB435 breast 
cancer cell line, both the ER receptor and HER2/neu expressions are absent (Table 1). 
 
Breast cancer 
cell lines 
ER receptor HER2/neu 
IC50 (g/mL) Doxorubicin 
(positive 
control) 
Lyophilized 
fruit juice
Cucurbitacin B
MDA-MB435 Negative Negative 155.77  0.14 25.84  0.83 0.48  0.05 
SKBR3 Negative Overexpressed 130.52  0.17 73.29  0.88 0.65  0.13 
MCF7 Positive Negative 374.77  0.19 34.52  0.11 0.62  0.04 
T47D Positive Negative 249.32  0.40 60.26  0.61 0.63  0.04 
Table 1. Cytotoxicity of the fruit juice of T. cucumerina (Kongtun et al., 2009). 
The mechanism that cucurbitacin B inhibits the breast cancer cell can be explained through 
the increased telomerase expression, which is associated with the neoplastic growth. Over 
90% of breast cancer has highly telomerase expression. We investigated the effect of 
cucurbitacin B on telomerase activity. Cucurbitacin B inhibited telomerase activity especially 
in the ER-negative breast cancer cell SKBR3 with IC50 of 3.29 g/mL, wheras TC compound 
4.6 g/mL and the lyophilized fruit juice less than 10 g/mL. The activity of human 
telomerase reverse transcriptase (hTERT) and the level of c-Myc protein were also decreased 
by cucurbitacin B. Thus cucurbitacin B possibly inhibited the breast cancer cell by reducing 
the telomerase activity via down regulating both hTERT and c-Myc expressions 
(Duangmano et al, 2010). Cucurbitacin B inhibited also lung and especially colon cancer cell 
lines (Kummalue et al, 2009). The recent research indicated the strong cancerostatic action of 
cucurbitacins B which worked through Jak/STAT-signal ways (Jak = Janus-kinase; STAT = 
signal transducer and activator of transcription). Cucurbitacin B specifically inhibited STAT 
3 which involved in the formation of interleukin 6 (IL-6), an important mediator in immune 
system (Haensel  Sticher, 2007). Cucurbitacin B was possible to act as immunosuppressive 
agent according to its inhibition of PHA-activated PBMC (U-pratya et al, 2010). 
2.1.2 Murdannia loriformis (Hassk.) Rolla Rao et Kammathy 
M. loriformis is commelinaceous, and monocotyledonous, perennial herb, about 10 cm high. 
The leaves are simple, glabrous, and alternate. The leaf blade is linear about 1.5-2.0 cm wide, 
15-20 cm long. The flowers are inflorescence, terminal and densely panicle. The pedicels 
slightly curved, translucent bracts about 4 mm, sepal ovate-elliptic, about 3 mm; petals blue or 
bluish violet (Fig.3). The plant is also used in traditional Chinese medicine as a remedy for 
detoxification and respiratory tract complaints (Book of traditional Chinese medicine in 
Sichuan, 1992). 
For over 30 years pressed herb juice from M. loriformis has been used to support self-
medication in Thailand by patients who suffer from different types of cancer. It is supposed 
to prolong the patient’s life and reduce the side effects resulting from modern therapy 
(radiation and chemotherapy) (Report from the first seminar on herbs and cancer, 1988). 
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Fig. 3. Murdannia loriformis Rolla Rao et Kammathy. 
The phytochemical work on this plant indicated the presence of cytotoxic glycosphingolipid 
namely 1-O-D-glucopyranosyl-2-(2-hydroxy-6-ene-cosamide)-sphingosine (Fig. 4) which 
had moderate cytotoxicity with ED50 of 10.7, 15.6, 18.9 and 32.5 molL-1 against human 
breast, lung, colon and liver cancer cell lines, respectively, whereas the positive control 
(quercetin) had the ED50 of 23.2, 13.2, 24.8 and 59.6 molL-1, respectively (Jiratchariyakul et 
at., 1997, 1998, 2006).  
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Fig. 4. Structure of 1-O-D-glucopyranosyl-2-(2-hydroxy-6-ene-cosamide)-sphingosine, a 
glycosphingolipid from M. loriformis. 
The investigation of the indirect (immune-mediated) cytotoxicity was also carried out. The 
pressed herb juice and the isolated cytotoxic glycosphingolipid were not toxic to the 
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peripheral blood mononuclear cells (PBMCs) in vitro. Both increased PBMCs proliferation in 
the presence of the mitogen PHA (phytohaemagglutinin); the glycosphingolipid had the 
stronger effect. The pressed juice slightly increased the CD3, 4 : CD3, 8 ratio in the 3 day 
culture and the glycosphingolipid increased this ratio at both the 3 and 7 day cultures. They 
were the indicative of an in vitro immunomodulatory effect of the pressed juice and the 
glycosphingolipid (Jiratchariyakul et al., 2006). 
The pressed juice had LD50, orally in rats, more than 120 g/kg body weight, and did not 
damage the growth, the blood chemistry and the pathology of organs. It was safe according 
to World Health Organization (Tappayuthpijarn et al., 1991; Intayot et al., 2002). The sub-
chronic toxicity study of M. loriformis in rats for 3 months did not damage the growth, the 
blood chemistry and the pathology of organs (Tappayuthpijarn et al., 1991). The ethanol 
extract of this plant induced in vitro DT-diaphorase, a detoxifying enzyme 
(Vinitketkumnuen, 1996), and decreased in vivo the formation of aberrant crypt foci (ACF), 
which was related to the colon cancer (Intayot et al., 2002). 
2.1.3 Ficus hispida L. f. 
F. hispida is a traditional Thai plant from family Moraceae. It is a moderate sized tree and 
grows well in damp and shady place (Fig. 5). Almost all parts of this plant can be used in 
traditional medicine for the treatment of various ailments, for example, an anti-diarrhea, 
emetic, astringent, hepatoprotective, antitussive, antipyretic, antiinflammatory, depurative, 
vulnerary, hemostatic, antiulcer as well as in the treatment of anemia (Wuttidhammaved, 
1997; Mandal and Ashok Kumar, 2002; Peraza-Sanchez et al., 2002). 
 
  
Fig. 5. Ficus hispida L. f. 
F. hispida, was investigated for antiproliferative activity on human breast cancer cell lines: 
SKBR3, MDA-MB435, T47D, and MCF7. Based on the results, the methanolic extract 
exhibited the most powerful activity on T47D breast cancer cell line with ED50 of 110.3±9.63 
g/mL as compared to DMSO, the negative control. Confirmation of the result using 
colony-forming assay (clonogenic assay) yielded the effect in a dose - dependent manner. 
The cell cycle analysis of this plant extract revealed non-specificity with prominent in 
apoptosis. Therefore, F. hispida might provide some benefits in the treatment of breast 
cancer. (Pratumvinit et al., 2009) 
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2.1.4 Erycibe elliptilimba Merr. & Chun. 
Erycibe elliptilimba, belonging to the Convolvulaceae family, is a Thai medicinal plant that 
has long been used for many decades to relieve symptoms from fever caused by infection, 
inflammation and prescribed in the mixture of traditional medicine for treating of various 
malignancies (Wuttidhammaved, 1997; Sintusarn, 2002). 
 
 
Fig. 6. Erycibe elliptilimba Merr. & Chun. 
The ED50 values of the methanol fraction against SKBR3 and MDA-MB435 were 56.07 and 
30.61 g/mL, respectively. Doxorubicin as a positive control. This inhibitory growth activity 
of the treated cells acted in a dose-dependent manner which was also confirmed by the cell 
viability with the trypan blue exclusion assay. (Kummalue et al., 2007).  
2.2 Herbal mixture 
Two Thai remedies (TR1 and TR2) were tested for antiproliferative effect. TR1 was 
composed of following ingredients : Albizia procera (stem), Diospyros mollis (stem), Ficus 
hispida (stem), Smilax glabra (stem), Smilax china (stem) and cobra bone. TR2 was composed 
of Gelonium multiflorum (stem), Erycibe elliptilimba (stem), Balanophora abbreviate (stem), 
Smilax glabra (stem), Smilax china (stem) and Millingtonia hortensis (stem). TR1 and TR2 had 
no antiproliferative effect on breast, lung and colon cancer cell lines. However the 
combination of the remedies (either TR1 or TR2, 30 g/mL) with doxorubicin (0.5 g/mL) 
could significantly inhibit growth of lung cancer cell line (A549) at G2/M phase stronger 
than doxorubicin alone (Srisapoomi et al., 2008).  
In addition two Thai medicinal plants, they were P. indica and S. rarax, were tested for 
antiproliferative effect. P. indica inhibited the leukemic cancer cells (NB4, HT93A) (U-pratya 
et al., 2008) and S. rarax inhibited the lung cancer cell (A549) (Kummalue et al., 2011). Both 
did not inhibit the breast cancer cell. 
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3. The herbal preparation  
The usage of herbs nowadays has been developed according to the laboratory evidence. 
Herbs are prepared as drug materials, which are conformed to the following pattern 
(Dingermann, 2000). 
 The nature (crude drug, tincture, pressed juice, fluidextract, dry extract, etc.) of the drug 
material (drug composition) must be specified.  
 The quantity of the drug material in each dose of the solid dosage form (tablets) or in 
each package of the liquid dosage form must be specified.  
For example:  200 mg dry extract / tablet or  
  100 mL fluidextract 
 The drug extract ratio (DER), the amount (g) of crude drug to produce one g extract or 
drug material, and the extraction method must be specified. 
 The solvent or solvent mixture used for the extraction must be specified. 
 The indication must be conformed to the monograph established by the Ministry of the 
Public Health, or supported by the clinical evidence. 
 The daily dose must be specified as the weight of the crude drug.  
For example : 
labeled DER  = 4-6.7 : 1 
recommended daily dose = 500 mg extract 
thus, the daily dose = 2-3.35 g crude drug.  
3.1 The preparation of Trichosanthes cucumerina 
 
 Declaration 
The drug material comprises pressed juice from T. cucumerina fruit, which 
is standardized with cucurbitacin B, a specific marker compound. 
 DER 
10.5:1 
One g pressed juice is prepared from 10.5 g fresh fruit. 
 According to the preparation which is made from the pressed juice it is non-drug and 
can be considered as traditional remedy (Haensel  Hoelzl, 1996). The indication is 
supported by the laboratory evidence and the traditional use. It is supposed to be used 
as natural cytostatic agent. 
 The daily dose 
10.5 g fresh fruit 
3.2 The preparation of Murdannia loriformis 
 
 Declaration 
The drug material comprises pressed juice from M. loriformis herb, which 
is standardized with glycosphingolipid namely 1-O-D-glucopyranosyl-2-
(2-hydroxy-6-ene-cosamide)-sphingosine, a specific marker compound. 
 DER 
1.7:1 
One g pressed juice is prepared from 1.7 g fresh herb. 
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 According to the preparation made from the pressed juice it is non-drug and can be 
considered as traditional remedy (Haensel  Hoelzl, 1996). The indication can be 
supported by the traditional use over 30 years and the case reported by the physicians. 
To use as an adjunct to anticancer therapy in order to reduce the side effects and 
prevent the cancer metastasis. 
 The daily dose 
100 g fresh herb (aerial plant parts) 
4. Breast cancer cells and experimental procedure in antiproliferative activity 
background 
Breast cancer is one of the leading causes of cancer death around the world. In Thailand, the 
incidence of breast cancer disease accounts for 20.5 per 100,000 female population 
(Chaiwerawatana, 2007). Though breast cancer treatment nowadays has dramatically 
improved due to new drug emerging such as monoclonal antibody, and tyrosine kinase 
inhibitor, the resistance to the drug itself, unfortunately, has significantly increased. 
Therefore, searching for the new drug to treat breast cancer is very essential. Based on this 
important issue, four specific breast cancer cell lines, i.e., SKBR3, MCF7, T47D, and MDA-
MB435 have been used to evaluate the potential and promising chemotherapeutic agents 
from medicinal plants sources. 
These four breast cancer cell lines, SKBR3, MCF7, T47D, and MDA-MB435, have different 
origins and properties which are considered as the very useful tools for investigating the 
medicinal plants effects. Actually, medicinal plants have long been prescribed for over 
centuries to treat various diseases including infections and malignancies such as breast 
cancer in many countries, for example, China, and Thailand. This traditional medicine 
nowadays plays an important role in healthcare system with approximately 80% of people 
around the world using it (Itharat and Ooraikul, 2007). Determination of the plants activities 
especially growth inhibition and their mechanisms for cancer therapy is, indeed, 
undergoing in much effort. 
In this section, four breast cancer cell lines and their experiments on medicinal plants are 
demonstrated. These include antiproliferative activity and cytotoxicity, cell cycle study, 
apoptotic study, mechanisms of action in plants, and future direction for testing the drugs 
from plant sources. Most of the experiments are performed in the biosafety level 1 which is 
suitable enough for manipulating these breast cancer cell lines in vitro. 
4.1 Breast cancer cell lines: Their origins and properties  
Breast cancer cell lines can be categorized into three groups according to their phenotypes 
and invasiveness (Lacroix and Leclercq, 2004). 
The first group is luminal epithelial-like cells. This group expresses high amount of typical 
luminal epithelial phenotype of breast cells such as estrogen receptor (ER), E-cadherin (gene 
CDH1), zonula occludens-1(TJP1), desmoplakin I/II (DSP), and desmosomal junctions. This 
group of breast cancer cells will grow as interconnected colonies of polygonal cells on plastic 
and as fused colonies in Matrigel, which is semisolid medium. This kind of cells are weakly 
invasive. BT-483, MCF7, T47D, and ZR-75 are all in this group. 
The second group is called weakly luminal epithelial-like cells. This group of cells shows the 
expression closely to the first group with a reduced extent or at least some of those markers. 
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Cells are weakly invasive in vitro. In Matrigel, most of these cells grow as non-fused 
spheres. Moreover, on plastic, they will accumulate in clusters of loosely attached cells and 
rarely reach full confluency. Breast cancer cell lines in this group are BT-474, CAMA-1, 
MDA-MB134, MDA-MB361, MDA-MB453, MDA-MB468, and SKBR3. 
The third group is mesenchymal-like or stromal-like cells. It does not express the markers 
found in the first and second group. In contrast, it exhibits a high level of vimentin (gene VIM) 
which is the marker of mesenchymal cells. These cells have fibroblastoid phenotype on plastic 
and grow as colonies with large stellate projections in Matrigel. They are highly invasive in 
vitro. MDA-MB435S, MDA-MB231, Hs578T, and BT-549 are classified in this group. 
Herein, details of breast cancer cell lines which have been employed in our medicinal plant 
research are demonstrated. 
4.1.1 SKBR3 breast cancer cell line  
SKBR3 is a human breast carcinoma cell line established in late 1970s and derived from 
pleural effusion of Caucasian patient diagnosed as invasive ductal carcinoma (CLS, 
Germany). It is an adherent cell which is the usual character found in most breast cancer cell 
lines. Ultra structures of cells show microvilli and desmosomes, large lysosomes, and 
bundles of cytoplasmic fibrils. In nude mice, these cells can form poorly differentiated 
adenocarcinoma (http://www.cell-lines-service). In addition in nude mice, c-Jun, the 
ending molecule of signal transduction pathways, is demonstrated to have the critical role in 
the tumorigenesis and metastasis in SKBR3 breast cancer cells (Zhang et al, 2007). 
Estrogen receptor (ER) is found to be absent or expressed at the very low level in SKBR3 
cells and progesterone receptor is also absent in this type of cell (Lacroix and Leclercq, 2004). 
In contrast, Her2/neu receptor including leptin receptor are overexpressed in this cell line 
whereas insulin- like growth factor receptor- I is expressed at the lower level when 
compared with those in MCF7 cells (Ozbay and Nahta, 2008). Interestingly, recent report 
revealed that SKBR3 expressed NMDAR1 and NMDAR2 receptors, both of which are 
important calcium channels. These receptors are reported to be essential for the growth of 
human breast cancer xenografts in mice (North et al, 2010).  
This SKBR3 cell line with high expression of HER2 protein has long been used in various 
research. Recently, it has been shown to be the suitable candidate for reference materials in 
quality control of HER2 testing together with MCF7 cell line. Based on this report, SKBR3 
and MCF7 breast cancer cells provide valuable controls for quantitative measurement of 
HER2 amplification and production (Xiao et al, 2009). The photograph of SKRB3 cultured in 
the flask is shown in Figure 7. 
4.1.2 MCF7 breast cancer cell line 
MCF7 is a human breast carcinoma cell line derived from pleural effusion of Caucasian 
patient diagnosed with breast adenocarcinoma (CLS, Germany). It is a relatively resistant to 
cisplatin treatment (Westmose Yde and Issinger, 2006). Morphology of this cell line exhibits 
epithelial-like cell including the ability to process estradiol via cytoplasmic estrogen 
receptors and domes formation. This cell line has oncogene, wnt7h and can induce tumor in 
nude mice (http://www.cell-lines-service).  
This MCF7 cell line expresses both estrogen and progesterone receptors whereas the 
expression of Her2/neu is absent (Lacroix and Leclercq, 2004). The cells can be suppressed 
by catechin hydrate, product from plant sources such as green tea, through TP53/caspase- 
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Fig. 7. SKBR3 cells grow in DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin+ streptomycin. Cells show monolayer when grow in plastic with polygonal 
shaped. This cell line is categorized as weakly luminal epithelial-like cell. 
mediated apoptosis (Alshatwi, 2010). Some vasoactive peptides such as endothelin 1 is 
found at low level in MCF7 while in SKBR3 is expressed at the higher level. This expression 
might correlate with high invasiveness phenotype in breast cancer (Hagemann et al, 2005).  
MCF7 has been extensively used as the model for breast cancer and breast cancer therapy. 
However, different sources of MCF7 show the differences in response to 17beta-estradiol 
resulting from activation or inhibition of insulin-like growth factor I (IGF-1) (Hamelers et al, 
2003). Therefore, the different responses of MCF7 should be realized due to the expression 
of IGF-1. As mentioned above, MCF7 is suitable to be candidate of reference materials in 
quality control for HER2 testing (Xiao et al, 2009). 
4.1.3 T47D breast cancer cell line 
T47D is a human breast carcinoma cell line derived from pleural effusion of an infiltrating 
ductal carcinoma of the breast (CLS, Germany). It contains cytoplasmic junctions, receptors 
to 17 beta estradiol including steroids and calcitonin ( Moseley et al, 1983). Receptors for 
estrogen and progesterone are also present (Hevir et al, 2011). This cell line has 
tumorigenicity in nude mice and has three oncogenes, i.e., wnt3, wnt7h, and wnt7b 
(http://www.cell-lines-service). 
By activation Janus kinase2/signal transducer and transcription 5 pathway, this cell line 
expresses ample growth hormone receptor and prolactin receptor (Xu et al, 2011). Both 
receptors are structurally similar cytokine receptor superfamily members. Direct protein 
identification by MALDI post-source decay (PSD) or MALDI collision-induced dissociation 
(CID) in T47D cells showed only histone H2B (Pevsner et al, 2007). Chemokine CXCL12 and its 
promoter activity are found to be increase in human T47D breast cancer cells (Chen et al, 2010). 
Indeed, T47D cell line, as well as MCF7, represents the good model of estrogen-dependent 
breast cancer with capacity of 17beta-estradiol local production (Hevir et al, 2011). 
4.1.4 MDA-MB435 breast cancer cell line 
MDA-MB435 is derived from the pleural effusion of metastatic ductal adenocarcinoma of 
the breast. Recent data have pointed out that MDA-MB435 cells are from melanoma 
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(Lacroix, 2009; Rae et al, 2004). This cell line is found to express certain genes commonly 
transcribed in melanocyte which are not seen in breast cancer cell lines such as DCP gene. 
Moreover, expression of melanocyte proteins tyrosinase and melan-A has also been 
demonstrated in MDA-MB435. However, some evidences have been presented that MDA-
MB435 might be breast cancer cell line expressing a poorly differentiated aggressive breast 
tumor together with epithelial and melanocyte markers (Chambers, 2009; http://www.cell-
lines-service). 
Investigation on protein identification in MDA-MB435 cells was performed and found 30 
important proteins expressing in this cell line (Chandramouli et al, 2009). For example, 
caspase 14 precursor, heat shock protein 60, cell adhesion proteins, and some immune 
response proteins such as complement C3 were also demonstrated. 
4.2 Breast cancer cells: Experimental procedures in antiproliferative activity 
Antiproliferative and cytotoxic activity are the basic and very common investigations used 
for determination in the efficacy of plant extracts for searching the novel drugs. The 
measurement of herb treated mammalian cells either surviving or proliferating cells could 
be achieved by several techniques. Counting cells that include or exclude a dye such as 
trypan blue dye with the use of a hemocytometer under a microscope or in an automated 
cell counter is one assay. Quantitation of suspension cells could be performed by counting 
them directly whereas adherent cells which grow in monolayer culture require proteolytic 
agents such as trypsin prior to quantitation. This method is, therefore, not only time 
consuming, labor intensive, but also dependent upon individual skills.  
A number of various indirect methods to quantitate living or dead cell number has been 
developed. Based on the fact that active or living cells will increase or decrease some specific 
proteins or even nucleic acids that can indicate cellular proliferation or cytotoxicity. 
Measuring released 51Cr-labeled protein after cell lysis, and measuring incorporation of 3H-
thymidine during cell proliferation have been employed (Mosmann, 1983). These traceable 
radioactive moieties are very efficient and specific. However, the radioactive methods could 
handle very limited numbers of samples at each time and also require long sample 
preparation procedure with inherent dangers and high cost (Haslam et al, 2000). Therefore, 
several non-radioactive methods have been developed instead of an old traditional method, 
the cell counting.  
In this section, breast cancer cells and experimental procedures in antiproliferative activity, 
three non-radioactive assays, i.e., MTT assay, Lactate dehydrogenase (LDH) cytotoxicity 
assay, and clonogenic assay, commonly used have been demonstrated in details. 
4.2.1 MTT assay 
Principle & mechanism of action 
This colorimetric assay was first developed and reported by Mosmann (Mosmann, 1983). 
Tetrazolium salt MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) is 
tested and used in this assay. These tetrazolium salts can measure the activity of several 
dehydrogenase enzymes especially mitochondrial enzyme succinate-dehydrogenase (Slater 
et al., 1963). The reaction is known to be occurred in the living cells by cleaving the 
tetrazolium ring in the metabolically active mitochondria, not in dead cells or erythrocytes. 
From the MTT pale yellow substrate, the dark blue (purple) formazan products are 
generated in the direct proportion to the living cell numbers. Notably, this MTT assay 
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cannot distinquish between the cytotoxic and cytostatic effect of the tested drug or herb 
(Plumb, 2004). 
Interestingly, MTT solution at 1 mg/mL increases the formazan product whereas MTT 
solution at 1-2 mg/mL will slow down the production (Sylvester, 2011). This is the reason 
why MTT solution is usually used at the concentration of 1 mg/mL. From the kinetics of 
formazan production, incubation time over 4 hours will get the plateau production curve. 
Therefore, standard incubation time at 3-4 hours is usually enough for the production time 
(Denizot and Lang, 1986).  
As reported, the blue formazan products are partially dissolved in the medium. To induce 
complete solubilization of these MTT formazan products, several organic solvents have been 
tested and used such as ethanol, dimethylsulfoxide (DMSO), and isopropanol which is 
reported to be the most suitable solvent. After getting the homogeneous solution, optical 
density (OD) will be measured by reading on a scanning multiwell spectrophotometer (ELISA 
reader). The absorption spectrum of MTT formazan crystal is pH dependent. At pH 10.5, the 
maximum absorption is 570 nm. whereas, at pH 7.0, the absorption peak will show at 500 and 
570 nm. (Plumb, 2004). The use of flat-bottomed well will help in increasing the sensitivity due 
to the doubled light-path length in the final optical density reading (Denizot and Lang, 1986).  
In general, the accurate and reliable results from the MTT assay depend upon various 
important parameters which need to be optimized first. The proper cell number for seeding 
should be characterized by using standard curve. Changing into fresh medium prior to 
adding MTT solution is also critical in getting the good yield because of reduction of MTT 
activity in nutrient-depleted medium. Time and dose of MTT solution in each experiment 
may be different for each cell or cell lines used (Sylvester, 2011). Importantly, 
chemotherapeutic agents and some drugs such as valproic acid can yield the lower results 
from the MTT assay (Ari et al, 2010; Ulukaya et al, 2008). The experimental procedure is as 
followed (Kummalue et al, 2005).  
Experimental procedure: 
 Breast cancer cells will be seeded at 1x104 cells per well in 96 flat-bottomed well plate 
containing 100µl of the culture medium DMEM supplemented with 10% heat 
inactivated fetal bovine serum and 1% antibiotic.  
 After 24 hours, the cells will be treated with herbal extract at final concentrations from 
1, 10, 100, and 500 µg/mL for 48 hours. These serial concentrations are used for 
determining the activity in crude extracts only.  
 After 48 hours incubation, medium will be changed into fresh medium, and MTT 50 µl 
(stock concentration at 1mg/mL in PBS) will be added to each well.  
 After 4 hours incubation, the MTT solution will then be removed by rapid flick-off of the 
medium and 100 µl of 100% DMSO will be added to solubilize the formazan products. 
The dark purple solution from formazan products can be seen as shown in Figure 8. 
 Plate will be rotated on the platform rotator for 10 minutes before further measurement 
the O.D. by a microplate Elisa reader at 595 nm. 
 Calculation of ED50 (50% of inhibition of cancer cell growth) will be performed by using 
the formula: 
 percentage of viability = OD sample/OD control  100 (1) 
percentage of inhibition = 100 - % viability 
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Special comments: 
 For pure compounds, serial concentrations can be diluted to the final concentrations as 
low as 0.1 µg/mL. This is because pure compounds are active compounds which are 
purified from crude extracts. 
 After adding MTT solution, remember to wrap plate with aluminium foil because MTT 
substrate is light sensitive. 
 We usually perform the O.D. measurement at 595 nm. because of the limitation of our 
instrument. 
 Rotate the cell culture plate at the rotator platform for 10 minutes is important to induce 
the homogeneous solution that will be easy for the O.D. measurement and to achieve 
the correct data. 
 The rapid flick-off of the medium after the MTT incubation will be done only in 
adherent cell lines such as breast cancer cell lines. For suspension cells such as leukemic 
cell lines, K562, the 100 µl of the stop solution (10% SDS dissolved in 0.01 N HCl) will be 
added into each well and incubated overnight. 
 If dilute the herbal extract with DMSO, it is better to keep the percentage of DMSO in 
the final concentration not more than 0.5% to avoid cell damage and false positive 
result. In our experience, 1% DMSO still can cause some effect on cell viability. 
 Please remember to set the control wells (both positive and negative control). We 
usually use doxorubicin or vinca alkaloid for positive control. Only cells in the medium 
will be used as negative control. 
 The number of the seeding cells used in our experiment is from the standard curve at 
the O.D 0.7-1.2.  
 We always perform the MTT assay with three independent experiments.  
 
 
Fig. 8. The MTT assay showed the dark purple formazan products in the wells after 
dissolving the crystal with 100 µl of 100% DMSO. 
4.2.2 Lactate dehydrogenase (LDH) cytotoxicity assay 
Principle & mechanism of action 
For MTT tetrazolium salt assay, the method measures the surviving cells after treatment 
with chemical substances. However, for the very low toxic reagents, calculation from the 
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data of control cells and treated cells from MTT assay results in low sensitivity. In this case, 
direct measurement of dead cells will give more accurate information (Sasaki et al, 1992). 
Therefore, development of assay using cytolytic enzymes releasing from dead cells has been 
initiated which can represent proportionally to the dead cell number (Sasaki et al, 1992). 
Detection of lactate dehydrogenase enzyme, one of the stable cytolytic enzyme found in 
animal cells, has been established for this purpose (Decker and Lohmann-Matthes, 1988). 
Lactate dehydrogenase (LDH) enzyme has the function to catalyze lactate to pyruvate under 
anaerobic condition. It is a soluble enzyme in the cytoplasm. This enzyme will be released to 
the culture medium when the cell is ruptured or dead. Usually the assay will contain two 
steps. First, LDH releasing from the cells will oxidize lactate to generate NADH and H+. The 
second step, diaphorase in the reaction will use NADH and H+ to catalyze the tetrazolium 
salt such as WST-8, or INT to generate colored formazan which will absorbs strongly at 
wavelength 490-520 nm. The amount of the formazan production will correlate in the 
proportion to the damaged cells in the reaction (Haslam et al, 2000; Rodney et al, 1966). The 
experimental procedure is shown belowed (Kummalue et al, 2009; LDH-cytotoxicity assay 
kit with WST-8, MBL international corporation). 
Experimental procedure: 
 Breast cancer cells will be seeded at a density of 1 x 104 cells per well in 96 well plates 
flat-bottom in 100 µl of culture medium DMEM supplemented with 10% heat 
inactivated fetal bovine serum and 1% antibiotic. 
 The next morning, cells will be treated with the herbal extract at various final 
concentrations from 1 to 500 µg/mL for 48 hours in the incubator. These concentrations 
are used to evaluate the ED50 for crude extracts only. 
 Centrifuge the cells at 1500 rpm or 250 g for 10 minutes. 
 Transfer 10 µl of culture medium into the new 96 well plate with corresponding well. 
 Add 100 µl of LDH reaction mix (containing LDH and WST-8) to 10 µl of tested culture 
medium and incubated at 37 ºC with a 5% CO2 incubator for an additional 30 minutes.  
 The absorbance at 450 nm of the dissolved solution will be measured by using an Elisa 
plate reader. 
Special comments: 
All MTT, WST-8, XTT, and INT are commonly used tetrazolium salts. They have different 
chemical structures and properties such as solubility. These properties depend on the 
substituents on the tetrazole rings in the compounds (Zhivich et al, 1990).  
4.2.3 Clonogenic assay 
Principle & mechanism of action 
This method for cell sensitivity assay is considered as the gold standard technique and has 
been used for a long time (Plumb, 2004). It is a well known method for testing the effects of 
drugs on the proliferation of treated cell lines. This assay can measure the ability of cells to 
proliferate and form colonies after treating cells with chemical substances or herbal extracts 
(cytostatic effect of drug) whereas cells that are killed by the drugs cannot grow and form 
colonies (cytotoxic effect of drug). In addition, clonogenic assay is reported to be able to 
detect cell survival as low as 1% (Plumb, 2004). 
Staining technique is a very important step because the accuracy of counting colonies 
depends on the good visualization. Colony staining has been performed with several dye  
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solutions such as methylene blue, ethidium bromide, and crystal violet (Guda et al, 2007). 
Counting colony can be done by using manual counting with microscope or using the 
specific software (Niyazi et al, 2007). The experimental procedure is demonstrated belowed 
(Pratumvinit et al, 2009). 
Experimental procedure: 
 Breast cancer cell lines will be plated in 12 well plate at a density of 7x102 cells per well.  
 The next morning, cells will be treated with the herbal extract at the concentrations of 0, 
50, 100, and 150 µg/mL.  
 After 48 hours incubation, culture medium will be changed into fresh medium.  
 Cells will be further cultured for 7-14 days until colonies are observed. 
 Plates will be stained with 1 gm of crystal violet in 50% methanol for 30 minutes. 
 Pour off the stain, carefully rinse with running water. 
 Colonies will be counted by using ChemiDocXRS with specific software. Figure 9 
showed the colonies detected in our experiment. 
Special comments: 
 The number of cells seeded in each well will be vary depending on the area of the well. 
 The concentrations used in the experiment depend upon the ED50 value of each 
medicinal plant. 
 Changing into fresh medium (after treated cells) before continue keeping cells in culture 
is very important for cell growth and colony formation. 
 The time for culturing after exposure to the herbal extract depend upon the cell growth 
curve. For breast cancer cell lines, small colony can be detected after culturing cells for 
at least 7 days.  
 Counting the colonies can be achieved by using only light microscope, no software use 
(but may be too difficult to count in some cases). 
 We always perform the clonogenic assay with three independent experiments. 
 
   
            A      B             C 
Fig. 9. Demonstration of colonies detected in the well. A. T47D breast cancer cells as a 
negative control. B. T47D treated with plant extract at 0.5 times ED50. No colony was 
detected which was due to the cytotoxicity of the extract. C. T47D treated with 0.5% DMSO 
as a control because the extract was diluted with 0.5% DMSO. Colonies could be seen as 
dots at the bottom of the wells after staining with crystal violet in this experiment and 
counted by using the software. 
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4.3 Breast cancer cells and experimental procedures in mechanism of actions 
This is usually the next step of investigation in searching for the new drug from plant 
sources. Plant extracts that exhibit the promising ED50 values, i.e., the plant extracts show 
some antiproliferative or cytotoxic activities on specific breast cancer cell lines, the extracts 
will be further studied to find the mechanism of actions in view of inhibition of cancer cells 
growth or even killing cells. Cell cycle analysis and apoptotic study are the most two 
common methods used in the field for searching the mechanism of actions in plants. 
4.3.1 Breast cancer cells and experimental procedure in cell cycle study 
Based on the knowledge of normal cell cycle, breast cancer cells actively synthesize DNA in 
the same process (Ross et al, 2003). Normally, the cell cycle phase contains G0, G1, S, G2, 
and M phase in order. Cells in the G0 phase or resting state contain diploid DNA which will 
enter the second step G1 (Gap 1). After this step, cells increase their DNA content to two 
folds with twice the diploid DNA content at the end. This accumulation state of DNA is S 
phase. Cells then enter the G2 phase (Gap 2) and finally go into the M phase, while M means 
the mitotic state. Finally, each mitotic cell will end up with 2 daughter cells. 
In breast cancer cells, DNA ploidy has been reported to correlate with the prognosis in 
patients. The first retrospective report using flow cytometry to study DNA content as a 
predictor in breast cancer was done by Auer et al with pure diploid showing an excellent 
prognosis (Auer et al, 1980). However, the use of DNA ploidy as an prognostic indicator in 
clinical practice still remains in controversy (Ross et al, 2003). Estrogen has also been 
reported to induce breast cancer which might due to the inappropriate activation of cyclin 
dependent kinase and consequently abnormal transition through G1 phase (Foster et al, 
2001). 
The most popular technique used for demonstration DNA content in the cells is by flow 
cytometry (Nunez, 2001). Four distinct phases could be categorized, i.e., G1, G2, S, and M 
phases with G2 and M phase will represent at the same DNA content (so called G2/M 
phase). The staining techniques to distinquish these cell cycle phases are the measurement 
of the incorporation of bromodeoxyuridine (BrdU) and propidium iodide (Kummalue et al, 
2002; Pratumvinit et al, 2009). Interference from RNA may result in misinterpretation as 
false positive. Therefore, the use of RNase should be added in the protocol. The experiment 
in breast cancer demonstrated here will share the experience in using the cell cycle kit which 
is much easier than the traditional technique. (The details of cell cycle study using BrdU 
incorporation and propidium iodide can be found in the references as mentioned in the 
text.) Belowed is the experimental procedure (Kummalue et al, 2007). 
Experimental procedure: 
 Breast cancer cells will be seeded at 1x106 cells in 100 mm tissue culture dish and 
incubated overnight. 
 The next morning, cells will be treated with the plant extract at the dosage ranging from 
0.5 times ED50 to 2 times ED50.  
 After 48 hours incubation, cells will be harvested and incubated with reagents as 
described in the protocol of the CycleTEST™PLUS DNA reagent kit (Becton Dickinson, 
USA). 
 Measurement of DNA content of cells will be performed within 3 hours by flow 
cytometry and analysed by CellQuest Software. 
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Special comments: 
 The incubation time for cell cycle study depends on the time that is used for cell 
sensitivity assay.  
 Dosage used in the experiment to investigate the effect of plant on cell cycle depends 
upon the ED50 of the plant extract. 
4.3.2 Breast cancer cells and experimental procedure in apoptotic study 
Apoptosis or programmed cell death is a very interesting investigation in drug discovery 
and development especially for cancer therapies. Searching for the anticancer agents that 
can induce apoptosis is necessary and needed for the effective treatment. For example, 
tamoxifen, which is prescribed as an adjuvant therapy in breast cancer, has been shown to 
induce apoptosis by down regulation of bcl-2 (Zhang et al, 1999). Therefore, most of 
medicinal plant researchers keep looking on finding these properties of plants. By the way, 
high cost and time consumption are unavoidable to face.  
Apoptosis is a process that organisms, including human beings, use to tightly regulate the 
cell numbers and tissue size (Hengartner, 2000). It is caused by a group of cysteine 
proteases known as caspases. There are 2 major apoptotic pathways. One is via death 
receptor pathway which is triggered by death receptor superfamily such as CD95 and also 
tumor necrosis factor receptor I. This results in activation of caspase 8. The other pathway 
is mitochondrial pathway. This activates pro-apoptotic member of the Bcl-2 family and 
then pro caspase 9. Both pathways converge at the caspase 3 activation (Hengartner, 
2000). To evaluate the apoptotic activity of plant extracts, caspase activity is usually 
investigated either by detection at the level of the enzyme caspase itself or by the level of 
its cleavage product, poly (ADP-ribose) polymerase-1 (PARP-1) (Los et al, 2002; 
Kummalue et al, 2011).  
In summary, characterization of apoptosis is chromatin condensation, fragmentation of 
DNA (seen as ladder pattern in gel electrophoresis), and reduction of cell volume. 
Externalization of phosphatidylserine at the cell surface also plays an important role in 
macrophages recognition and consequently eradication of these apoptotic cells (Koopman et 
al, 1994). With these specific expression of phosphatidylserine, the new method was 
developed for detection of apoptotic cells by flow cytometry and has been frequently used 
nowadays. (Koopman et al, 1994). The experimental procedure is shown belowed. 
(Kummalue et al, 2011) 
Experimental procedure: 
 Cells will be seeded on 100 cm tissue culture dish at the density of 1x106 cells.  
 After 24 hours, cells will be treated with plant extracts at the various final 
concentrations ranging from 0.5 times ED50, to 2 times ED50. 
 After incubating cells for various time points, cells will be harvested. The time points 
used to treat cells depend on the efficacy of the plant extract itself.  
 Cells will be labeled with Annexin V-PI following the protocol of Annexin V-FITC 
Apoptosis Detection Kit from the manufacture and analysis by flow cytometry. 
Special comments: 
Detection of early and late apoptosis using annexin V depends upon the doses and time    
that treating the cells.  
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4.3.3 Breast cancer cells and specific mechanism of action of the plant extracts 
Elucidation of the mechanism of action will greatly help in understanding the activity from 
plant sources on these breast cancer cell lines. Following the cell cycle and apoptotic studies 
as the basis, the mechanisms of these activities such as telomerase activity, antioxidant 
activity, and details of special signaling pathways are always considered for studying.  
Telomerase is a eukaryotic ribonucleoprotein complex that helps in stabilizing telomere 
length in human stem cells, reproductive cells, and cancer cells (Shay and Bacchetti, 1997; 
Shay et al, 2001). The activity of telomerase increases in almost all human cancers except for 
the normal cells (Shay et al, 2001;Kim et al, 1994). Based on several studies, there are 
correlations between telomere shortening and growth failure of human cells (Harley et al, 
1990; Shay et al, 2001). Therefore, human cancer cells show to have short telomeres with 
high telomerase, which is in contrast to normal human cells. Notably, cancer cells need to 
maintain telomeres for their immortalization. Based on this correlation, investigations of 
human cancer on telomerase activity have been done for over decades due to the potential 
development in drug targeting cancers. 
Human telomerase consists of a catalytic protein component (hTERT) and integral RNA 
which are essential for the function of telomerase (Shay et al, 2001). hTERT is reported to be 
the critical for the production of telomerase (Nakamura et al, 1997). Investigation on 
telomerase activity can usually perform by detection the hTERT expression using RT-PCR. 
RNA extraction from treated breast cancer cells will be done before further processing to 
quantitate the level of transcripts. The method can be undertaken by real time RT-PCR and 
specific software for interpretation (Duangmano et al, 2010). 
5. Breast cancer cells in medicinal plants research: Future direction in drug 
testing 
Generating of induced pluripotent stem cells (iPS) for the first time in the world by 
Professor Dr. Shinya Yamanaka in Year 2006 has very high impact on several fields such as 
stem cell therapies, regenerative medicine, replacement therapy, and also drug screening 
and toxicity (Inoue and Yamanaka, 2011). Researchers worldwide are very interested in this 
iPS technology because of the high possibility in its usefulness and application to human 
diseases. 
Induced pluripotent stem cells or iPS has first been generated from mouse tip tail fibroblasts 
which were somatic cells (Takahashi and Yamanaka, 2006). The process involved in 
transduction of fibroblasts with retrovirus carrying 4 transcription factors, i.e., Sox2, Klf4, c-
Myc, and Oct3/4. These four factors are now known as Yamanaka’s four factors. iPS cells 
exhibit several features characteristics of embryonic stem cells such as positive for alkaline 
phosphatase, forming teratoma in mice, and expression of specific embryonic antigen (Park 
et al, 2008). Nowadays, iPSs have been generated from various kinds of animals cells such as 
monkey, mouse, etc., including normal human cells, human cancer cell lines, and patients’ 
cells to generate the patient-specific iPSs (Chun et al, 2010; Raya et al, 2009). 
In drug screening and toxicity testing, human iPSs offer the high values in this field. For 
example, breast cancer patients’ fibroblasts can be induced with transcription factors either 2 
or 4 factors to create patient-specific iPS. Based on the fact that the iPS cells are generated 
from patients’ own somatic cells, therefore, these specific iPS cells can be used to identify 
and test with the novel drug developing for cancer patients including the toxic effects of the 
drugs themselves (Chun et al, 2010). Interestingly, the advantage of iPS is the generation of 
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the library for human cancer that will represent the genetic and epigenetic variation of the 
population (Chun et al, 2010). In addition, since iPSs grow in culture like cell lines, therefore, 
this technology can provide the unlimited sources of cells for desired situation. 
6. Discussion and conclusion 
The investigation of the traditional used and evidence-based medicinal plants provides the 
chance to discover natural anticancer agents. The breast cancer cell lines with specific 
properties and the progress in antiproliferative and cytotoxic experiments are the important 
tools for the investigation of the medicinal plants. Clear differences in specific properties 
including receptors of these 4 breast cancer cell lines have been demonstrated so far. 
Comparing specific receptors, i.e., estrogen receptor, progesterone receptor, and Her2/neu 
in these 4 breast cancer cell lines: SKBR3, MCF7, T47D, and MDA-MB435 are demonstrated 
in Table 2. These 4 breast cancer cell lines are classified in different groups and express 
different receptors. Therefore, treatment of plant extracts on these 4 breast cancer cell lines 
can help, at least, in the decision whether or not the extracts will exert activities in breast 
cancer with different subtypes. However, the established cell lines from patients do not 
always represent the genotypes of parental tumor tissues (Tsuji et al, 2010). Therefore, 
testing in cell lines may not yield the same results when performing in vivo though most of 
these cells deregulate in signaling along the EgfR-MAPK pathway (Heiser et al, 2009). 
 
Characters SKBR3 MCF7 T47D MDA-MB435 
Category Second group First group First group Third group 
Estrogen receptor - + + - 
Progesterone 
receptor 
- + + - 
Her-2/neu overexpression - - - 
(-) = not expressed; (+) = expressed 
Table 2. Characters of receptors on four breast cancer cell lines: SKBR3, MCF7, T47D, and 
MDA-MB435 (http://www.cell-lines-service; Lacroix and Leclercq, 2004; Hevir et al, 2011). 
Searching for the novel chemotherapeutic agents from plant sources usually involves with 
the initial process of antiproliferative activity. These three non-radioactive assays are 
commonly used nowadays in the determination of antiproliferative and cytotoxic activities. 
Several aspects from them are summarized in Table 3, i.e., sensitivity, cost and time 
consuming for each assay. Notably, each assay has its own advantages and disadvantages 
which should be carefully considered. 
Prediction of toxicology and therapeutic responses induced by the novel drugs can be 
approached by iPS technology as mentioned aboved. Lots of current disease specific based 
patients iPS have been reported since then (Chun et al, 2010). This application as a 
personalized approach leads to the specialized model in vitro. However, the safety and risk 
in applying to the clinical trials should be aggressively considered because of the techniques 
in generation of iPS with viral gene transfer. 
The elucidation of the action mechanism provides the concrete evidence of the study plant. 
The utilization of herbs as natural anticancer agents can solve the problem of the  
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 MTT assay LDH assay with  
WST-8 
Clonogenic assay 
Sensitivity ++ 
(high sensitivity for 
antiproliferative 
activity) 
+++ 
(high sensitivity for 
cytotoxic activity) 
+ 
(low sensitivity and high false 
negative result due to small 
colony formation) 
Cost 
consuming 
++ 
(high cost reagent) 
++ 
(high cost reagent) 
+ 
(low cost staining) 
Time 
consuming 
++ 
(moderate term culture) 
+ 
(short term culture) 
+++ 
(long term culture and time 
spending in counting) 
+++ represent the highest scores 
     + represent the lowest scores 
Table 3. Comparison of three non-radioactive methods for assaying the antiproliferative 
activities (Kosaka et al, 1996; Kawada et al, 2002; Fotakis and Timbrell, 2006; Miyamoto et al, 
2002). 
unaccessible anticancer drugs. We investigated thoroughly two Thai herbs and discovered 
the possible benefit to the breast cancer patients. T. cucumerina fruit juice exerted strongly 
antiproliferative effect. The juice itself can be considered as a natural cytostatic agent 
because of its potent effect. According to the presence of cucurbitacins, the juice irritates the 
mucous membrane of the gastrointestinal tract. The juice produced toxicity to the central 
nervous system and the respiratory tract, the usage of the herbal juice should be under the 
supervision of the physician.  
For the part of M. loriformis herb juice, it can be used as an adjunct to the modern therapy 
according to the moderate cytotoxicity, immunomodulatory effect and safety. The patient 
cases, which were reported by the physicians, have supported the use of herbal juice to 
reduce the side effects from the modern therapy. Several active compounds in the pressed 
juice worked together to exert the activities, which were expected to have broad spectrum 
and lowered toxicity. The appropriate daily doses of cytotoxic effect from T. cucumerina and 
immunomodulatory effect from M. loriformis require further clinical investigation. 
F. hispida and E. elliptilimba are interesting herbs for further investigation. It was also 
noticeable that herbal remedy could potentiate the effect of anticancer drug. 
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